Novavax Secures $60 Million in Government Funds

Novavax announced a $60 million contract with the US Department of Defense to support the production of several components of NVX‑CoV2373, its COVID-19 vaccine candidate. The agreement includes delivery in 2020 of 10 million doses of NVX‑CoV2373 that can be used in Phase 2/3 clinical trials or under an Emergency Use Authorization if approved by FDA.

In a June 4, 2020 press statement, Novavax reported that the company will work with US-based contract development manufacturing organizations (CDMOs) to manufacture the antigen component of NVX-CoV2373 for at least 10 million doses of vaccine and will collaborate with US-based CDMOs to scale up production and manufacture of the Matrix-M adjuvant component of the vaccine.

Previously, Novavax announced that it has secured two manufacturing agreements for the large-scale manufacture of components of the vaccine candidate.